Morphine Market Valued at $24.8 Billion in 2024 Amid Rising Chronic Disease Burden and Unequal Global Access

Morphine market was valued at $24.8 billion in 2024 and is projected to reach $40.1 billion in 2035, growing at a CAGR of 4.8% during the forecast period (2025-2035). Chronic diseases, commonly referred to as non-communicable diseases, are lengthy health conditions such as heart disease, cancer, diabetes, and respiratory conditions, that are currently the major cause of death globally. The WHO indicates that, on average, 75% of global deaths are attributed to chronic diseases (with 43 million deaths in 2021). About 18 million chronic disease-related deaths occur before the age of 70, with many of these deaths in low- and middle-income countries. The reason behind this disease is excessive use of tobacco, physical inactivity, the harmful use of alcohol, unhealthy diets, and air pollution, all increase the risk of dying from an NCD.

Browse the full report description of “Morphine Market Size, Share & Trends Analysis Report by Dosage Form (Tablets, Capsules, Oral Liquids, and Injections), by Application (Major Trauma, Post-Surgical Pain, Labor Pain, and Cancer-Related Pain), by End User (Hospitals & Clinics, and Ambulatory Surgical Centers), Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/morphine-market

As these conditions progress to advanced and painful stages, morphine becomes essential. Its effectiveness in managing severe, persistent pain in palliative and end-of-life care makes it a critical tool for relieving suffering—yet access remains hampered by regulatory barriers and supply inequalities. In 2023, 81 per cent of the global population—primarily residing in low- and middle-income countries accounted for only 15 per cent of the total morphine consumption used for pain and suffering management. The remaining 85 per cent of morphine consumption was concentrated in a limited number of countries, mainly in Europe and North America. This stark imbalance in the use of narcotic drugs for palliative care remains a serious concern, particularly regarding equitable access to and the affordability of opioid analgesics such as morphine.

Market Coverage

• The market number available for – 2024-2035

• Base year- 2024

• Forecast period- 2025-2035

• Segment Covered- 

o By Dosage Form

o By Application

o By End User

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape - Mallinckrodt plc, Pfizer Inc., Taj Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Mayne Pharma Group Limited, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Morphine Market Report Segment

By Dosage Form

• Tablets
• Capsules
• Oral Liquids
• Injections

By Application

• Major Trauma 
• Post-Surgical Pain
• Labor Pain
• Cancer-Related Pain

By End User

• Hospitals & Clinics
• Ambulatory Surgical Centers

Global Morphine Market Report Segment by Region

North America

• United States

• Canada 

Europe

• UK

• Germany

• Italy

• Spain

• France

• Russia

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Australia and New Zealand

• ASEAN Economies

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/morphine-market